Skip to main content
. 2024 Mar 4;130(9):1463–1476. doi: 10.1038/s41416-024-02621-x

Fig. 2. Loss of Gal3 effect on cell proliferation and cell viability.

Fig. 2

a cell counts in ARK1 cells, b cell counts in ARK2 cells, c The percentage of each stage of cell cycle in ARK1 cells. d The percentage of each stage of cell cycle in ARK2 cells. e Immunoblotting of cell cycle regulatory proteins representative of the G2/M phase in ARK1 cells. E Immunoblot of EGFR and pEGFR in lysates from ARK cell lines 72-hours post-treatment with GB1107. f Immunoblot of ERK1/2 and pERK1/2 in lysates from ARK cell lines 72-hours post-treatment with GB1107. g and h MTT assay using carboplatin in SKOV3 or ARK1 cells after 72 h exposure, respectively. i MTT assay using carboplatin in ARK2 cells after 72 h exposure, j, k and L BH3 profiling in SKOV3, ARK1 and ARK2 cells, respectively. In all experiments, Gal3 knockdown or knockout cells were compared to corresponding controls. Significance was calculated using t-test with * indicating P < 0.05, ** indicating P < 0.01, *** indicating P < 0.001, and **** indicating P < 0.0001. Significance was calculated using Šidák correction (cell cycle assay) and t-test (others) with * indicating P < 0.05, ** indicating P < 0.01,*** indicating P < 0.001 and **** indicating P < 0.0001.